Clinical Trials Logo

Juvenile Myoclonic Epilepsy clinical trials

View clinical trials related to Juvenile Myoclonic Epilepsy.

Filter by:
  • None
  • Page 1

NCT ID: NCT06153186 Terminated - Clinical trials for Childhood Absence Epilepsy

Flunarizine for Treatment Resistant Absence Epilepsy

Start date: September 20, 2019
Phase: Phase 2
Study type: Interventional

This is an open-label, single-centre study to evaluate the clinical efficacy, safety and tolerability of Flunarizine administered as adjunctive treatment in participants diagnosed with treatment resistant absence epilepsy. The study goal is to see how efficient and safe flunarizine is at decreasing the frequency of absence seizures in children with treatment-resistant refractory epilepsy at doses of 5mg and 10mg once daily.

NCT ID: NCT03400371 Recruiting - Clinical trials for Juvenile Myoclonic Epilepsy

Biology of Juvenile Myoclonic Epilepsy

BIOJUME
Start date: July 13, 2017
Phase:
Study type: Observational

The investigators are collecting genetic information through blood samples as well as clinical and EEG data from over 1000 people with Juvenile Myoclonic Epilepsy (JME) across the UK, Europe and North America. This study will draw on both existing and new samples from JME patients. These will be compared to anonymised data from samples for 2000 controls. The goal of this study is to find the genetic cause of JME. Finding the cause will help create better treatments for JME, as well as improve patient outcomes by allowing us to detect it earlier.